Skip to main content
. Author manuscript; available in PMC: 2021 Apr 10.
Published in final edited form as: Leukemia. 2020 Aug 7;35(4):1023–1036. doi: 10.1038/s41375-020-1003-x

Figure 6. Alternating THU+Dec with THU+5Aza week to week.

Figure 6.

NSG mice were tail-vein inoculated with patient-derived AML cells (1×106cells/mouse) and randomized to the treatments shown (n=5/group). Blood counts were obtained periodically by tail-vein phlebotomy. Mice were euthanized for signs of distress. A) Experiment schema; B) Time-to-distress. Log-rank test. C) Serial blood counts. Measured by Hemavet. Median±IQR. D) Bone marrow replacement by AML. Bone marrow human and murine CD45+ cells measured by flow-cytometry (Figure S4) after euthanasia (time-points panel B). Median±IQR. p-value Mann-Whitney test 2-sided. E) DNMT1 was not depleted from AML cells at progression (time-points panel B) but was depleted at time-of-response (bone marrow harvested at Day 63 in a separate experiment). Flow cytometry (Figure S5). F) Pyrimidine metabolism gene expression in bone marrow AML cells. QRT-PCR using human gene specific primers, bone marrow harvested after euthanasia. p-values vs vehicle, unpaired t-test, 2-sided.